These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 19241338)
1. Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer. Nowroozi MR; Zeighami S; Ayati M; Jamshidian H; Ranjbaran AR; Moradi A; Afsar F Urol J; 2009; 6(1):27-30. PubMed ID: 19241338 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Lee AK; Levy LB; Cheung R; Kuban D Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415 [TBL] [Abstract][Full Text] [Related]
3. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM; Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837 [TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Semeniuk RC; Venner PM; North S Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728 [TBL] [Abstract][Full Text] [Related]
5. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Khatami A; Hugosson J; Wang W; Damber JE Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633 [TBL] [Abstract][Full Text] [Related]
6. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Lin DD; Schultz D; Renshaw AA; Rubin MA; Richie JP; D'Amico AV Urology; 2005 Mar; 65(3):528-32. PubMed ID: 15780370 [TBL] [Abstract][Full Text] [Related]
7. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer. Beard C; Chen MH; Cote K; Loffredo M; Renshaw A; Hurwitz M; D'Amico AV Urology; 2005 Nov; 66(5):1020-3. PubMed ID: 16286116 [TBL] [Abstract][Full Text] [Related]
8. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy. Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856 [TBL] [Abstract][Full Text] [Related]
9. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730 [TBL] [Abstract][Full Text] [Related]
10. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867 [TBL] [Abstract][Full Text] [Related]
11. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706 [TBL] [Abstract][Full Text] [Related]
12. PSA doubling time post radiation: the effect of neoadjuvant androgen ablation. Tyldesley S; Coldman A; Pickles T; Can J Urol; 2004 Aug; 11(4):2316-21. PubMed ID: 15460601 [TBL] [Abstract][Full Text] [Related]
13. [PSA and follow-up after treatment of prostate cancer]. Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065 [TBL] [Abstract][Full Text] [Related]
14. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983 [TBL] [Abstract][Full Text] [Related]
15. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence. Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456 [TBL] [Abstract][Full Text] [Related]
16. Optimal measure of PSA kinetics to identify prostate cancer. Benecchi L; Pieri AM; Destro Pastizzaro C; Potenzoni M Urology; 2008 Mar; 71(3):390-4. PubMed ID: 18342170 [TBL] [Abstract][Full Text] [Related]
17. Critical analysis of prostate-specific antigen doubling time calculation methodology. Svatek RS; Shulman M; Choudhary PK; Benaim E Cancer; 2006 Mar; 106(5):1047-53. PubMed ID: 16456812 [TBL] [Abstract][Full Text] [Related]
18. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070 [TBL] [Abstract][Full Text] [Related]